ArticleMolecular medicine reports2026
Histone deacetylase 3‑mediated histone deacetylation combined with activating transcription factor 3 promotes renal fibrosis by inhibiting Klotho.
Article in Molecular medicine reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Renal fibrosis is a representative pathological trait of renal aging and chronic kidney disease. However, the regulatory mechanisms of histone deacetylation in renal fibrosis remain unclear. A mouse renal fibrosis model was constructed using the unilateral ureteric obstruction method, and HK2 cells treated with TGF‑β were used to create a renal fibrosis cell model. Low expression of Klotho in renal fibrosis is associated with histone deacetylase 3 (HDAC3)‑mediated histone deacetylation. After TGF‑β treatment, H3K9ac and Klotho binding was markedly decreased, while H3K9ac was enriched in the Klotho group after the addition of the HDAC3 inhibitor. Further experiments demonstrated that HDAC3 binding activates transcription factor 3, inhibits Klotho transcription and promotes cellular renal fibrosis. The absence of Klotho may activate the Wnt/β‑catenin and NF‑κB pathways to promote oxidative stress and inflammation, thereby exacerbating the fibrotic process. HDAC3 binds to ATF3 to transcriptionally repress Klotho, leading to activation of the Wnt/β‑catenin and NF‑κB pathways and exacerbation of renal fibrosis.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.